Investment Thesis
PMGC Holdings demonstrates fundamentally broken economics with only $682K in quarterly revenue against $7.7M in operating losses, indicating a pre-commercial or failed commercial product. Despite adequate near-term liquidity, the company is burning $3M+ in quarterly operating cash flow with an unsustainable cost structure and no clear path to profitability.
Strengths
- No material debt with 0.00x debt/equity ratio provides financial flexibility
- Adequate liquidity with $14.4M cash and 1.45x current ratio for near-term survival
- Positive gross margin of 33.8% shows underlying product has reasonable unit economics
Risks
- Critically low revenue of $682K suggests failed commercialization or pre-revenue stage for a pharmaceutical company
- Operating expenses are 11x revenue generating $7.7M quarterly operating losses and -1136.3% operating margin
- Negative operating cash flow of $3M quarterly will deplete cash reserves in 4-5 years without dramatic operational improvement
Key Metrics to Watch
- Quarterly revenue trend and product sales breakdown by indication
- Monthly operating cash burn rate and cash runway extension
- FDA approvals, pipeline updates, and commercial execution metrics
Financial Metrics
Revenue
682.0K
Net Income
-5.0M
EPS (Diluted)
$-0.23
Free Cash Flow
-3.3M
Total Assets
26.0M
Cash
14.4M
Profitability Ratios
Gross Margin
33.8%
Operating Margin
-1,136.3%
Net Margin
-728.3%
ROE
-39.4%
ROA
-19.1%
FCF Margin
-490.1%
Balance Sheet & Liquidity
Current Ratio
1.45x
Quick Ratio
1.43x
Debt/Equity
0.00x
Debt/Assets
51.6%
Interest Coverage
-42.03x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:07:08.315866 |
Data as of: 2026-03-31 |
Powered by Claude AI